Pharvaris (PHVS) has released an update.
Pharvaris, a biopharmaceutical company, has announced positive progress in its clinical trials for deucrictibant, an oral treatment for hereditary angioedema (HAE), with two Phase 3 studies underway and a solid financial standing of €344 million in cash reserves as of Q2 2024. The company is advancing its prophylactic and on-demand treatments for HAE with global clinical development plans and aims to bring new oral therapies to the HAE community. Pharvaris highlights its commitment to providing effective and well-tolerated treatments for HAE, supported by continuing presentations at medical conferences and a disciplined approach to its financial resources.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.
